```html

Xanthoma of the Tendon – A Comprehensive Medical Guide

Overview

Xanthoma of the tendon (also called tendon xanthoma or familial tendinous xanthoma) is a benign, lipid‑rich deposit that forms within the body’s tendons, most commonly the Achilles, hand extensor, and quadriceps tendons. The lesions appear as firm, yellow‑orange nodules that are usually painless, but may become tender or limit motion if they grow large.

• Typical age of onset: 20–40 years, though they can appear earlier in children with severe familial hyperlipidemia.
• Gender: Slight male predominance (≈ 1.3 : 1).
• Prevalence: Tendon xanthomas occur in < 2 % of the general population but are present in up to 25 % of patients with familial hypercholesterolemia (FH) and in 50 % of those with homozygous FH.<sup>[1][2]</sup>
• Associated conditions: They are a cutaneous marker for underlying lipid metabolism disorders, especially FH, but may also be seen with other dyslipidemias, cholestatic liver disease, or rare metabolic syndromes.

Symptoms

Most tendon xanthomas are discovered incidentally during a physical exam or when a patient notices a lump. The symptom spectrum includes:

Typical signs

• Firm, yellow‑orange nodules on tendons – most often the Achilles, extensor tendons of the hands, and the quadriceps tendon.
• Palpable thickening of the tendon that may be mistaken for a tendon tear or chronic inflammation.
• Localized tenderness when the nodule is pressed or the tendon is stretched.

Functional symptoms

• Reduced range of motion – large xanthomas can limit flexion or extension, especially in the hand or ankle.
• Weakness or “giving way” – the tendon may feel less firm, raising concern for rupture.
• Cosmetic concern – visible nodules on the hands or feet can cause psychological distress.

Systemic clues suggesting an underlying lipid disorder

• Early‑onset (< 45 y) coronary artery disease (CAD) or peripheral arterial disease.
• Family history of high cholesterol, heart attacks, or sudden cardiac death.
• Other xanthomas (e.g., eruptive, tuberous) or xanthelasma around the eyes.

Causes and Risk Factors

Tendon xanthomas are not a disease themselves; they are a manifestation of lipid accumulation within the tendon’s connective tissue.

Primary cause

• Familial hypercholesterolemia (FH) – an autosomal‑dominant mutation in the LDL‑receptor (LDLR), APOB, or PCSK9 genes leads to markedly elevated low‑density lipoprotein cholesterol (LDL‑C). The excess LDL particles infiltrate macrophages, become foam cells, and deposit cholesterol esters in tendons.

Secondary causes

• Secondary hyperlipidemia from uncontrolled diabetes mellitus, hypothyroidism, or nephrotic syndrome.
• Cholestatic liver disease (e.g., primary biliary cholangitis) that raises serum lipids.
• Rare metabolic disorders such as sitosterolemia.

Risk factors

• Genetic predisposition – carriers of FH mutations.
• Male sex (modestly higher risk).
• High‑fat diet and sedentary lifestyle that exacerbate dyslipidemia.
• Smoking – accelerates atherosclerosis and may worsen lipid profiles.
• Age – cumulative exposure to high LDL‑C increases the chance of tendon lipid deposition.

Diagnosis

Diagnosis combines a careful clinical exam with laboratory and imaging studies to confirm both the tendon lesion and the underlying lipid disorder.

1. Clinical examination

• Inspection for yellow‑orange nodules along tendons.
• Palpation to assess firmness, size, and tenderness.
• Functional testing of tendon strength and range of motion.

2. Laboratory tests

• Lipid panel – total cholesterol, LDL‑C, HDL‑C, triglycerides. In FH, LDL‑C often > 190 mg/dL in heterozygotes or > 400 mg/dL in homozygotes.
• Genetic testing for LDLR, APOB, PCSK9 mutations when FH is suspected (recommended by the American College of Cardiology).<sup>[3]</sup>
• Secondary causes: fasting glucose, HbA1c, thyroid‑stimulating hormone (TSH), liver function tests, and urine protein.

3. Imaging

• Ultrasound – readily shows hyperechoic, poorly vascularized nodules within the tendon; useful for differentiating from tendon tears.
• Magnetic resonance imaging (MRI) – provides higher soft‑tissue resolution; xanthomas appear as homogenous, T1‑hyperintense lesions embedded in the tendon matrix.
• CT scan – rarely needed but can demonstrate calcified components if present.

4. Histopathology (rarely required)

Biopsy shows foam cells (lipid‑laden macrophages) and cholesterol clefts within dense collagen. Most clinicians avoid biopsy because imaging plus lipid studies are sufficient.

Treatment Options

Management targets two goals: reduce the lipid burden to prevent new xanthomas and cardiovascular events, and address existing tendon lesions when they cause symptoms or cosmetic concerns.

1. Lipid‑lowering therapy – the cornerstone

• Statins (e.g., atorvastatin, rosuvastatin) – first‑line; reduce LDL‑C by 30‑55 %.
• Ezetimibe – added when statins alone are insufficient; provides an additional 15‑20 % LDL‑C reduction.
• PCSK9 inhibitors (evolocumab, alirocumab) – monoclonal antibodies that can lower LDL‑C > 60 % in refractory FH.<sup>[4]</sup>
• Bile‑acid sequestrants, fibrates, or niacin – used selectively, especially if triglycerides are high.
• Goal LDL‑C for FH: < 70 mg/dL (or < 55 mg/dL for very high‑risk patients) per ACC/AHA guidelines.<sup>[5]</sup>

2. Surgical and procedural options

• Excisional surgery – removal of the xanthoma when it is large, painful, or cosmetically undesirable. Requires careful tendon repair to avoid weakening.
• Liposuction‑assisted curettage – minimally invasive; useful for extensive hand lesions.
• Laser or radiofrequency ablation – experimental, limited data.

Procedures are reserved for patients who have achieved optimal lipid control but still have symptomatic nodules.

3. Lifestyle modifications

• Heart‑healthy diet – Mediterranean or DASH diet; <10 % of calories from saturated fat; increase soluble fiber (oats, legumes).
• Regular aerobic activity – at least 150 min/week of moderate‑intensity exercise.
• Weight management – aim for BMI < 25 kg/m².
• Smoking cessation – nicotine replacement therapy or counseling.
• Alcohol moderation – ≤ 2 drinks/day for men, ≤ 1 drink/day for women.

Living with Xanthoma of the Tendon

Even after treatment, many patients continue to notice the nodules. Practical strategies for daily life include:

• Footwear – Choose supportive shoes with cushioned heels to reduce pressure on Achilles‑tendon xanthomas.
• Hand ergonomics – Use padded grips when performing repetitive motions (e.g., typing, gardening) to limit tendon irritation.
• Regular monitoring – Schedule lipid panels every 3–6 months and a physical exam annually to assess nodule size.
• Skin care – Keep the overlying skin clean and moisturized; avoid trauma that could trigger inflammation.
• Psychological support – If cosmetic concerns cause distress, consider counseling or support groups for FH patients.
• Family screening – First‑degree relatives should have lipid testing and genetic counseling, as FH is hereditary.

Prevention

The most effective prevention is early detection and aggressive management of dyslipidemia.

• Universal cholesterol screening – At least once between ages 20–35, then every 4–6 years; earlier if family history is positive.<sup>[6]</sup>
• Genetic testing for at‑risk families – Allows cascade screening and early statin initiation, which can prevent xanthoma formation.
• Adopt heart‑healthy habits from childhood – diet, activity, and avoidance of tobacco.
• Control secondary contributors – Treat diabetes, hypothyroidism, and liver disease promptly.

Complications

If left untreated, tendon xanthomas themselves are benign, but the underlying lipid disorder can lead to serious sequelae:

• Atherosclerotic cardiovascular disease – premature coronary artery disease, myocardial infarction, stroke, and peripheral arterial disease. Patients with FH have a 20‑30 % risk of a heart attack before age 40.<sup>[7]</sup>
• Tendon rupture – Large infiltrated tendons are weaker and may tear with minor trauma.
• Functional impairment – Chronic pain or limited range of motion may affect work or sports.
• Psychosocial impact – Visible lesions can cause anxiety, depression, or reduced self‑esteem.

When to Seek Emergency Care

References

1. American Heart Association. Familial Hypercholesterolemia Fact Sheet. 2023.
2. Mayo Clinic. Tendon Xanthoma. Accessed May 2024.
3. Nordestgaard BG, et al. “Genetic Testing for Familial Hypercholesterolemia.” *Lancet* 2022;399: 571‑583.
4. Robinson JG, et al. “Efficacy and Safety of PCSK9 Inhibitors in FH.” *NEJM* 2021;384: 1735‑1745.
5. ACC/AHA Guideline on the Management of Blood Cholesterol. Circulation. 2022.
6. CDC. “Cholesterol Screening Recommendations.” Updated 2023.
7. Nordestgaard BG, et al. “Cardiovascular Risk in Familial Hypercholesterolemia.” *JACC* 2020;75: 2505‑2515.

```